

Margaret A Knowles

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6875869/publications.pdf>

Version: 2024-02-01

121
papers

8,367
citations

44069

48
h-index

46799

89
g-index

124
all docs

124
docs citations

124
times ranked

9854
citing authors

#	ARTICLE	IF	CITATIONS
1	Mutational landscape of non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 295-303.	1.6	31
2	From Fragment to Lead: De Novo Design and Development toward a Selective FGFR2 Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 1481-1504.	6.4	16
3	Molecular profile of pure squamous cell carcinoma of the bladder identifies major roles for <sc>OSMR</sc> and <sc>YAP</sc> signalling. <i>Journal of Pathology: Clinical Research</i> , 2022, 8, 279-293.	3.0	1
4	Modeling the mechanical stiffness of pancreatic ductal adenocarcinoma. <i>Matrix Biology Plus</i> , 2022, 14, 100109.	3.5	7
5	The Lund Molecular Taxonomy Applied to Non-“Muscle-Invasive Urothelial Carcinoma. <i>Journal of Molecular Diagnostics</i> , 2022, 24, 992-1008.	2.8	13
6	Affimer-based impedimetric biosensors for fibroblast growth factor receptor 3 (FGFR3): a novel tool for detection and surveillance of recurrent bladder cancer. <i>Sensors and Actuators B: Chemical</i> , 2021, 326, 128829.	7.8	10
7	An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. <i>Nature Communications</i> , 2021, 12, 2301.	12.8	159
8	The Warburg effect as a therapeutic target for bladder cancers and intratumoral heterogeneity in associated molecular targets. <i>Cancer Science</i> , 2021, 112, 3822-3834.	3.9	19
9	Stage-stratified molecular profiling of non-muscle-invasive bladder cancer enhances biological, clinical, and therapeutic insight. <i>Cell Reports Medicine</i> , 2021, 2, 100472.	6.5	13
10	A simple method for detecting oncofetal chondroitin sulfate glycosaminoglycans in bladder cancer urine. <i>Cell Death Discovery</i> , 2020, 6, 65.	4.7	5
11	FGFR3 “a Central Player in Bladder Cancer Pathogenesis?. <i>Bladder Cancer</i> , 2020, 6, 403-423.	0.4	7
12	Dysregulation at multiple points of the kynurenine pathway is a ubiquitous feature of renal cancer: implications for tumour immune evasion. <i>British Journal of Cancer</i> , 2020, 123, 137-147.	6.4	17
13	Report From the International Society of Urological Pathology (ISUP) Consultation Conference On Molecular Pathology Of Urogenital Cancers. II. Molecular Pathology of Bladder Cancer. <i>American Journal of Surgical Pathology</i> , 2020, 44, e30-e46.	3.7	38
14	Monitoring of urothelial cancer disease status after treatment by digital droplet PCR liquid biopsy assays. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 737.e1-737.e10.	1.6	12
15	ETV5 links the FGFR3 and Hippo signalling pathways in bladder cancer. <i>Scientific Reports</i> , 2019, 9, 5740.	3.3	15
16	Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus. <i>Molecular Therapy - Oncolytics</i> , 2018, 9, 1-12.	4.4	49
17	Multi-omic profiling refines the molecular view. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 203-204.	27.6	22
18	SnapShot: Bladder Cancer. <i>Cancer Cell</i> , 2018, 34, 350-350.e1.	16.8	27

#	ARTICLE	IF	CITATIONS
19	<i>FGFR3</i> mutation increases bladder tumourigenesis by suppressing acute inflammation. Journal of Pathology, 2018, 246, 331-343.	4.5	33
20	Patient-derived mutations within the N-terminal domains of p85Î± impact PTEN or Rab5 binding and regulation. Scientific Reports, 2018, 8, 7108.	3.3	12
21	Abstract 3991: Novel small molecule inhibitors of p300/CBP down-regulate androgen receptor (AR) and c-Myc for the treatment of prostate cancer and beyond. , 2018, , .		2
22	Bladder cancer. Nature Reviews Disease Primers, 2017, 3, 17022.	30.5	590
23	TRPA1â€™FGFR2 binding event is a regulatory oncogenic driver modulated by miRNA-142-3p. Nature Communications, 2017, 8, 947.	12.8	56
24	Identification of an Indazole-Based Pharmacophore for the Inhibition of FGFR Kinases Using Fragment-Led <i>de Novo</i> Design. ACS Medicinal Chemistry Letters, 2017, 8, 1264-1268.	2.8	13
25	Genomic Subtypes of Non-invasive Bladder Cancer with Distinct Metabolic Profile and Female Gender Bias in KDM6A Mutation Frequency. Cancer Cell, 2017, 32, 701-715.e7.	16.8	224
26	Unique signalling connectivity of FGFR3-TACC3 oncoprotein revealed by quantitative phosphoproteomics and differential network analysis. Oncotarget, 2017, 8, 102898-102911.	1.8	10
27	Affimer proteins are versatile and renewable affinity reagents. ELife, 2017, 6, .	6.0	151
28	TERT Core Promotor Mutations in Early-Onset Bladder Cancer. Journal of Cancer, 2016, 7, 915-920.	2.5	31
29	Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use. Oncotarget, 2016, 7, 24252-24268.	1.8	83
30	A place for precision medicine in bladder cancer: targeting the FGFRs. Future Oncology, 2016, 12, 2243-2263.	2.4	39
31	Summary and Recommendations from the National Cancer Instituteâ€™s Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. Bladder Cancer, 2016, 2, 165-202.	0.4	30
32	FIESTA: A phase Ib and pharmacokinetic trial of AZD4547 in combination with gemcitabine and cisplatin.. Journal of Clinical Oncology, 2016, 34, 4521-4521.	1.6	4
33	Fibroblast growth factor receptor (FGFR) alterations in squamous differentiated bladder cancer: a putative therapeutic target for a small subgroup. Oncotarget, 2016, 7, 71429-71439.	1.8	23
34	ToTem: A phase Ib trial of temsirolimus with gemcitabine and cisplatin.. Journal of Clinical Oncology, 2016, 34, e16032-e16032.	1.6	0
35	Abstract LB-323: The genomic landscape of non-muscle-invasive bladder cancer: implications for molecular classification and treatment. , 2016, , .		0
36	Polycomb Repressor Complex 1 Member, BMI1 Contributes to Urothelial Tumorigenesis through p16-Independent Mechanisms. Translational Oncology, 2015, 8, 387-399.	3.7	6

#	ARTICLE	IF	CITATIONS
37	Use of Aleuria alantia Lectin Affinity Chromatography to Enrich Candidate Biomarkers from the Urine of Patients with Bladder Cancer. <i>Proteomes</i> , 2015, 3, 266-282.	3.5	5
38	Towards a Next-Generation Sequencing Diagnostic Service for Tumour Genotyping: A Comparison of Panels and Platforms. <i>BioMed Research International</i> , 2015, 2015, 1-6.	1.9	12
39	The Effect of Mutations on Drug Sensitivity and Kinase Activity of Fibroblast Growth Factor Receptors: A Combined Experimental and Theoretical Study. <i>EBioMedicine</i> , 2015, 2, 194-204.	6.1	60
40	Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 53-64.	1.6	11
41	Alteration of Cell-Cell and Cell-Matrix Adhesion in Urothelial Cells: An Oncogenic Mechanism for Mutant FGFR3. <i>Molecular Cancer Research</i> , 2015, 13, 138-148.	3.4	18
42	Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. <i>Nature Reviews Cancer</i> , 2015, 15, 25-41.	28.4	928
43	FGFR3 Expression in Primary Invasive Bladder Cancers and Matched Lymph Node Metastases. <i>Journal of Urology</i> , 2015, 193, 325-330.	0.4	26
44	FGFR3 Translocations in Bladder Cancer: Differential Sensitivity to HSP90 Inhibition Based on Drug Metabolism. <i>Molecular Cancer Research</i> , 2014, 12, 1042-1054.	3.4	68
45	Frequent inactivating mutations of STAG2 in bladder cancer are associated with low tumour grade and stage and inversely related to chromosomal copy number changes. <i>Human Molecular Genetics</i> , 2014, 23, 1964-1974.	2.9	71
46	Comprehensive Mutation Analysis of the TERT Promoter in Bladder Cancer and Detection of Mutations in Voided Urine. <i>European Urology</i> , 2014, 65, 367-369.	1.9	137
47	MP28-20 PATHOLOGICAL VALIDATION OF ADJUVANT ANTI - FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) FOR PERSONALIZED TREATMENT OF BLADDER CANCER. <i>Journal of Urology</i> , 2014, 191, .	0.4	0
48	Assessing the quality of studies on the diagnostic accuracy of tumor markers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1051-1060.	1.6	16
49	Genome-wide association study yields variants at 20p12.2 that associate with urinary bladder cancer. <i>Human Molecular Genetics</i> , 2014, 23, 5545-5557.	2.9	46
50	Molecular Subtyping of Invasive Bladder Cancer: Time to Divide and Rule?. <i>Cancer Cell</i> , 2014, 25, 135-136.	16.8	33
51	Abstract 2240: TERT promoter mutations are highly prevalent in bladder cancer and represent a potential new urinary biomarker. , 2014, , .		2
52	Abstract 5256: Mechanism of field cancerization. , 2014, , .		0
53	Oncogenic FGFR3 gene fusions in bladder cancer. <i>Human Molecular Genetics</i> , 2013, 22, 795-803.	2.9	329
54	Expression of Engrailed-2 (EN2) protein in bladder cancer and its potential utility as a urinary diagnostic biomarker. <i>European Journal of Cancer</i> , 2013, 49, 2214-2222.	2.8	41

#	ARTICLE	IF	CITATIONS
55	Proteomic studies of urinary biomarkers for prostate, bladder and kidney cancers. <i>Nature Reviews Urology</i> , 2013, 10, 206-218.	3.8	78
56	An integrated genomic, transcriptional and protein investigation of <i>FGFR1</i> as a putative 4p16.3 deletion target in bladder cancer. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 860-871.	2.8	12
57	Parallel RNA Interference Screens Identify EGFR Activation as an Escape Mechanism in <i>FGFR3</i> -Mutant Cancer. <i>Cancer Discovery</i> , 2013, 3, 1058-1071.	9.4	103
58	Identification of Mutations in Distinct Regions of p85 Alpha in Urothelial Cancer. <i>PLoS ONE</i> , 2013, 8, e84411.	2.5	16
59	Abstract 5310: Activation of <i>FGFR3</i> by genomic fusion in urothelial carcinoma of the bladder.. , 2013, , .		0
60	Abstract C130: The Hsp90 inhibitor ganetespib promotes the degradation of <i>FGFR3</i> in bladder cancer models and induces regression in tumors harboring oncogenic <i>FGFR3</i> fusions.. , 2013, , .		0
61	A Decade of FGF Receptor Research in Bladder Cancer: Past, Present, and Future Challenges. <i>Advances in Urology</i> , 2012, 2012, 1-10.	1.3	101
62	Novel Tumor Subgroups of Urothelial Carcinoma of the Bladder Defined by Integrated Genomic Analysis. <i>Clinical Cancer Research</i> , 2012, 18, 5865-5877.	7.0	88
63	Urothelial Carcinoma. <i>Advances in Urology</i> , 2012, 2012, 1-2.	1.3	2
64	<i>FGFR1</i> -Induced Epithelial to Mesenchymal Transition through MAPK/PLC β /COX-2-Mediated Mechanisms. <i>PLoS ONE</i> , 2012, 7, e38972.	2.5	82
65	Abstract LB-152: PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signalling and phenotypic outputs. , 2012, , .		0
66	In vitro functional effects of XPC gene rare variants from bladder cancer patients. <i>Carcinogenesis</i> , 2011, 32, 516-521.	2.8	10
67	High-resolution analysis of genomic alteration on chromosome arm 8p in urothelial carcinoma. <i>Genes Chromosomes and Cancer</i> , 2010, 49, 642-659.	2.8	23
68	A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. <i>Nature Genetics</i> , 2010, 42, 415-419.	21.4	169
69	Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010, 28, 409-428.	1.6	156
70	Altered Splicing of <i>FGFR1</i> Is Associated with High Tumor Grade and Stage and Leads to Increased Sensitivity to FGF1 in Bladder Cancer. <i>American Journal of Pathology</i> , 2010, 177, 2379-2386.	3.8	57
71	Distinct MicroRNA Alterations Characterize High- and Low-Grade Bladder Cancer. <i>Cancer Research</i> , 2009, 69, 8472-8481.	0.9	291
72	Spectrum of Phosphatidylinositol 3-Kinase Pathway Gene Alterations in Bladder Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 6008-6017.	7.0	235

#	ARTICLE	IF	CITATIONS
73	Fibroblast Growth Factor Receptor 1 Promotes Proliferation and Survival via Activation of the Mitogen-Activated Protein Kinase Pathway in Bladder Cancer. <i>Cancer Research</i> , 2009, 69, 4613-4620.	0.9	111
74	A SNaPshot assay for the rapid and simple detection of four common hotspot codon mutations in the PIK3CA gene. <i>BMC Research Notes</i> , 2009, 2, 66.	1.4	90
75	Integrated genomic and transcriptional analysis of the in vitro evolution of telomerase-immortalized urothelial cells (TERT-hTERT). <i>Genes Chromosomes and Cancer</i> , 2009, 48, 694-710.	2.8	20
76	Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer. <i>Cancer and Metastasis Reviews</i> , 2009, 28, 305-316.	5.9	148
77	Molecular pathogenesis of bladder cancer. <i>International Journal of Clinical Oncology</i> , 2008, 13, 287-297.	2.2	105
78	Genomics: a preview of genomic medicine. <i>BJU International</i> , 2008, 102, 1221-1227.	2.5	8
79	Bladder cancer subtypes defined by genomic alterations. <i>Scandinavian Journal of Urology and Nephrology</i> , 2008, 42, 116-130.	1.4	45
80	Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms. <i>Human Molecular Genetics</i> , 2008, 17, 2006-2017.	2.9	50
81	Novel therapeutic targets in bladder cancer: mutation and expression of FGF receptors. <i>Future Oncology</i> , 2008, 4, 71-83.	2.4	62
82	Genes Involved in Differentiation, Stem Cell Renewal, and Tumorigenesis Are Modulated in Telomerase-Immortalized Human Urothelial Cells. <i>Molecular Cancer Research</i> , 2008, 6, 1154-1168.	3.4	42
83	Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target. <i>World Journal of Urology</i> , 2007, 25, 581-593.	2.2	108
84	Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?. <i>Carcinogenesis</i> , 2006, 27, 361-373.	2.8	222
85	FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. <i>Oncogene</i> , 2005, 24, 5218-5225.	5.9	295
86	Assessment by FISH of karyotypic complexity and cytogenetic evolution in bladder cancer in vitro. <i>Genes Chromosomes and Cancer</i> , 2005, 43, 315-328.	2.8	14
87	Comprehensive Analysis of CDKN2A Status in Microdissected Urothelial Cell Carcinoma Reveals Potential Haploinsufficiency, a High Frequency of Homozygous Co-deletion and Associations with Clinical Phenotype. <i>Clinical Cancer Research</i> , 2005, 11, 5740-5747.	7.0	56
88	Alternative Splicing of Fibroblast Growth Factor Receptor 3 Produces a Secreted Isoform That Inhibits Fibroblast Growth Factor-Induced Proliferation and Is Repressed in Urothelial Carcinoma Cell Lines. <i>Cancer Research</i> , 2005, 65, 10441-10449.	0.9	64
89	Infrequent mutation of TRAIL receptor 2 (TRAIL-R2/DR5) in transitional cell carcinoma of the bladder with 8p21 loss of heterozygosity. <i>Cancer Letters</i> , 2005, 220, 137-144.	7.2	24
90	Mutation analysis of the 8p candidate tumour suppressor genes DBC2 (RHOBTB2) and LZTS1 in bladder cancer. <i>Cancer Letters</i> , 2005, 225, 121-130.	7.2	70

#	ARTICLE	IF	CITATIONS
91	Loss of heterozygosity analysis and DNA copy number measurement on 8p in bladder cancer reveals two mechanisms of allelic loss. <i>Cancer Research</i> , 2005, 65, 66-75.	0.9	27
92	High-resolution analysis of genomic copy number alterations in bladder cancer by microarray-based comparative genomic hybridization. <i>Oncogene</i> , 2004, 23, 2250-2263.	5.9	133
93	Measurement of Relative Copy Number of CDKN2A/ARF and CDKN2B in Bladder Cancer by Real-Time Quantitative PCR and Multiplex Ligation-Dependent Probe Amplification. <i>Journal of Molecular Diagnostics</i> , 2004, 6, 356-365.	2.8	26
94	Fibroblast Growth Factors and Their Receptors in Transitional Cell Carcinoma. <i>Journal of Urology</i> , 2003, 169, 675-682.	0.4	38
95	Improved measurement of p16 and p14ARF gene dosage in bladder tumours by quantitative real time PCR. <i>European Urology Supplements</i> , 2003, 2, 35.	0.1	0
96	Mutation spectrum of the 9q34 tuberous sclerosis gene TSC1 in transitional cell carcinoma of the bladder. <i>Cancer Research</i> , 2003, 63, 7652-6.	0.9	79
97	Fibroblast growth factors and their receptors in transitional cell carcinoma. <i>Journal of Urology</i> , 2003, 169, 675-82.	0.4	9
98	Molecular genetic analysis of chromosome 9 candidate tumor suppressor loci in bladder cancer cell lines. <i>Genes Chromosomes and Cancer</i> , 2002, 34, 86-96.	2.8	35
99	Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma. <i>Oncogene</i> , 2001, 20, 686-691.	5.9	101
100	Hypermethylation at 9q32-33 tumour suppressor region is age-related in normal urothelium and an early and frequent alteration in bladder cancer. <i>Oncogene</i> , 2001, 20, 531-537.	5.9	71
101	Negative regulation of G1/S transition by the candidate bladder tumour suppressor gene DBCCR1. <i>Oncogene</i> , 2001, 20, 2956-2964.	5.9	54
102	Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours. <i>Oncogene</i> , 2001, 20, 4416-4418.	5.9	85
103	Redefining a critical region of LOH on 4p16.3 in bladder cancer. <i>Genes Chromosomes and Cancer</i> , 2000, 29, 378-379.	2.8	4
104	Two novel regions of interstitial deletion on chromosome 8p in colorectal cancer. <i>Oncogene</i> , 1999, 18, 657-665.	5.9	32
105	Mutation of the 9q34 gene TSC1 in sporadic bladder cancer. <i>Oncogene</i> , 1999, 18, 2657-2661.	5.9	119
106	Homozygous deletion at the 9q32-33 candidate tumor suppressor locus in primary human bladder cancer. <i>Genes Chromosomes and Cancer</i> , 1999, 26, 171-175.	2.8	34
107	Identification of novel bladder tumour suppressor genes. <i>Electrophoresis</i> , 1999, 20, 269-279.	2.4	33
108	Urological malignancies and the proteomic-genomic interface. <i>Electrophoresis</i> , 1999, 20, 3629-3637.	2.4	22

#	ARTICLE	IF	CITATIONS
109	A Sequence-Ready 840-kb PAC Contig Spanning the Candidate Tumor Suppressor Locus DBC1 on Human Chromosome 9q32â€“q33. <i>Genomics</i> , 1999, 59, 335-338.	2.9	16
110	Identification of novel bladder tumour suppressor genes. <i>Electrophoresis</i> , 1999, 20, 269-279.	2.4	1
111	Urological malignancies and the proteomic-genomic interface. <i>Electrophoresis</i> , 1999, 20, 3629-3637.	2.4	2
112	Structure and Methylation-Based Silencing of a Gene (DBCCR1) within a Candidate Bladder Cancer Tumor Suppressor Region at 9q32â€“q33. <i>Genomics</i> , 1998, 48, 277-288.	2.9	124
113	A Novel Candidate Tumour Suppressor Locus at 9q32â€“33 in Bladder Cancer: Localization of the Candidate Region Within a Single 840 kb YAC. <i>Human Molecular Genetics</i> , 1997, 6, 913-919.	2.9	75
114	Identification and Characterization of the Human Homologue of SH3BP2, an SH3 Binding Domain Protein within a Common Region of Deletion at 4p16.3 Involved in Bladder Cancer. <i>Genomics</i> , 1997, 44, 163-170.	2.9	37
115	DAP-kinase loss of expression in various carcinoma and B-cell lymphoma cell lines: possible implications for role as tumor suppressor gene. <i>Oncogene</i> , 1997, 15, 403-407.	5.9	190
116	Mutation analysis of 8p genes POLB and PPP2CB in bladder cancer. <i>Cancer Genetics and Cytogenetics</i> , 1997, 93, 167-171.	1.0	28
117	Fluorescence in situ hybridization deletion mapping at 4p16.3 in bladder cancer cell lines refines the localisation of the critical interval to 30 kb. <i>Genes Chromosomes and Cancer</i> , 1996, 17, 108-117.	2.8	20
118	Deletion mapping of chromosome II in carcinoma of the bladder. <i>Genes Chromosomes and Cancer</i> , 1995, 13, 1-8.	2.8	75
119	<i>p16 (CDKN2)</i> is a major deletion target at 9p21 in bladder cancer. <i>Human Molecular Genetics</i> , 1995, 4, 1569-1577.	2.9	169
120	The spectrum of TP53 mutations in bladder carcinoma. <i>Genes Chromosomes and Cancer</i> , 1994, 9, 108-118.	2.8	49
121	Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression. <i>International Journal of Cancer</i> , 1993, 53, 781-784.	5.1	146